Zydus Lifesciences Limited announced on May 13, 2026, that its subsidiary Zydus Worldwide DMCC has signed a definitive agreement to acquire all outstanding shares of Assertio Holdings, Inc. for USD 23.50 per share in cash, totalling approximately USD 166.4 million on a fully-diluted basis. Assertio is a U.S.-based specialty oncology company whose key product, ROLVEDON® (eflapegrastim-xnst), recorded adjusted turnover of USD 68.23 million in CY 2025 and USD 60.09 million in CY 2024. The transaction, structured as a tender offer followed by a merger, is expected to close in financial year 2026-27, subject to customary closing conditions and regulatory approvals. The acquisition is aimed at providing Zydus with an immediate U.S. specialty oncology commercial footprint, leveraging Assertio's 170+ community oncology accounts and buy-and-bill infrastructure.
Zydus Lifesciences to Acquire U.S. Specialty Oncology Firm Assertio Holdings for Approximately USD 166.4 Million
